Financial Performance - In the first half of 2025, the company achieved revenue of 3.658 billion CNY, a year-on-year increase of 4.77% [2] - Net profit attributable to shareholders reached 215 million CNY, representing a significant year-on-year growth of 115.33% [2] - Revenue from plant extraction products amounted to 1.733 billion CNY, with a year-on-year increase of 9.47% and a gross margin of 20.24%, up by 3.43% [2] Product Performance - Sales of the main product, chili red pigment, reached 6,367 tons, a year-on-year increase of 43% [3] - Chili extract sales grew to 1,536 tons, marking an 81% increase [3] - Lutein sales remained stable while promoting high-value products, with a focus on application-specific products [3] - Revenue from stevia glycosides exceeded 160 million CNY, driven by innovative processes [4] Business Strategy - The company adopted a "locking" strategy for cottonseed business to mitigate price volatility, achieving revenue of 1.765 billion CNY, a 2% increase [4] - The company plans to enhance market share for chili extract without immediate price increases, focusing on extending the processing chain [5] - The company aims to develop stevia and other tiered products into new major products, indicating significant growth potential [6] Research and Development - R&D expenses increased significantly due to changes in project structure and material costs, reflecting the company's commitment to innovation [9] - The company will continue to invest heavily in R&D while balancing costs and profits to ensure sustainable growth [9] Market Expansion - The company plans to expand its marigold planting in Myanmar, aiming to establish it as a key raw material source for lutein [7] - The company is enhancing its raw material supply chain by supporting suppliers and stabilizing market supply [8]

Core Viewpoint - The company, Morning Bio (300138.SZ), anticipates significant growth in its financial performance for the first half of 2025, driven primarily by the recovery in its cottonseed business and steady growth in its plant extraction segment [1][2]. Financial Performance Summary - The company expects to achieve revenue between 3.46 billion to 3.76 billion yuan, reflecting a year-on-year change of -0.89% to 7.71% [1]. - The projected net profit attributable to shareholders is estimated to be between 202 million to 232 million yuan, indicating a substantial year-on-year increase of 102.33% to 132.38% [1]. - The expected non-recurring net profit ranges from 174 million to 204 million yuan, with a remarkable growth rate of 117.40% to 154.88% compared to the previous year [1]. Business Segment Performance - The recovery in the cottonseed business is identified as the main factor influencing the company's performance, transitioning from losses to profitability due to improved market conditions [1]. - The plant extraction business, including products like chili red, chili essence, and steviol glycosides, has also contributed to the overall profit growth, with significant year-on-year increases in gross profit [1]. Strategic Insights - The company has committed to a locked-in operating model, which has effectively mitigated risks associated with price fluctuations in the cottonseed market, leading to a turnaround in profitability [1][2]. - The company anticipates that high prices for cottonseed protein and the implementation of new standards for lutein will provide ongoing growth momentum in the second half of the year [2].